Search Results - "Hodi, F Stephen"

The Intersection between Tumor Angiogenesis and Immune Suppression by Rahma, Osama E, Hodi, F Stephen

“…Both immune checkpoint inhibitors (ICI) and antiangiogenesis agents have changed the landscape of cancer treatment in the modern era. While antiangiogenesis…”
Get full text

Monitoring immune-checkpoint blockade: response evaluation and biomarker development by Nishino, Mizuki, Ramaiya, Nikhil H., Hatabu, Hiroto, Hodi, F. Stephen

“…Key Points A subset of patients receiving immune-checkpoint inhibitor therapy develop unconventional response patterns (termed 'pseudoprogression'), in which…”
Get full text

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions by Nishino, Mizuki, Hatabu, Hiroto, Hodi, F Stephen

“…Cancer immunotherapy using immune-checkpoint inhibitors has emerged as an effective treatment option for a variety of advanced cancers in the past decade…”
Get full text

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain by Tawbi, Hussein A, Forsyth, Peter A, Algazi, Alain, Hamid, Omid, Hodi, F. Stephen, Moschos, Stergios J, Khushalani, Nikhil I, Lewis, Karl, Lao, Christopher D, Postow, Michael A, Atkins, Michael B, Ernstoff, Marc S, Reardon, David A, Puzanov, Igor, Kudchadkar, Ragini R, Thomas, Reena P, Tarhini, Ahmad, Pavlick, Anna C, Jiang, Joel, Avila, Alexandre, Demelo, Sheena, Margolin, Kim

“…A combination of nivolumab and ipilimumab produced complete responses in 26% and partial responses in 30% of patients with previously untreated brain…”
Get full text

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade by Buchbinder, Elizabeth, Hodi, F Stephen

“…The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a…”
Get full text

Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 by CHEN, Daniel S, IRVING, Bryan A, STEPHEN HODI, F

“…The aim of T-cell-based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely…”
Get full text

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab by Ribas, Antoni, Hodi, F. Stephen, Callahan, Margaret, Konto, Cyril, Wolchok, Jedd

“…The independent mechanisms of action and largely nonoverlapping toxicity profiles of vemurafenib and ipilimumab made it logical to test them together in a…”
Get full text

Metabolomic adaptations and correlates of survival to immune checkpoint blockade by Li, Haoxin, Bullock, Kevin, Gurjao, Carino, Braun, David, Shukla, Sachet A., Bossé, Dominick, Lalani, Aly-Khan A., Gopal, Shuba, Jin, Chelsea, Horak, Christine, Wind-Rotolo, Megan, Signoretti, Sabina, McDermott, David F., Freeman, Gordon J., Van Allen, Eliezer M., Schreiber, Stuart L., Stephen Hodi, F., Sellers, William R., Garraway, Levi A., Clish, Clary B., Choueiri, Toni K., Giannakis, Marios

“…Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate…”
Get full text

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy by Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D

“…Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately…”
Get full text

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition by XIAOFENG JIANG, JUN ZHOU, GIOBBIE-HURDE, Anita, WARGO, Jennifer, STEPHEN HODI, F

“…Selective BRAF inhibition (BRAFi) provides a paradigm shift for melanoma treatment. The duration of benefit is typically limited before resistance develops…”
Get full text

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma by Schadendorf, Dirk, Hodi, F Stephen, Robert, Caroline, Weber, Jeffrey S, Margolin, Kim, Hamid, Omid, Patt, Debra, Chen, Tai-Tsang, Berman, David M, Wolchok, Jedd D

“…To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of…”
Get full text

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints by Chang, Lee-Shing, Barroso-Sousa, Romualdo, Tolaney, Sara M, Hodi, F Stephen, Kaiser, Ursula B, Min, Le

“…Abstract Immune checkpoints are small molecules expressed by immune cells that play critical roles in maintaining immune homeostasis. Targeting the immune…”
Get full text

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy by Nishino, Mizuki, Sholl, Lynette M, Hatabu, Hiroto, Ramaiya, Nikhil H, Hodi, F. Stephen

“…Among three patients with melanoma receiving anti–PD-1 antibodies, the use of checkpoint blockers led to the development of serious autoimmune pneumonitis, a…”
Get full text

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity by Ferrari de Andrade, Lucas, Tay, Rong En, Pan, Deng, Luoma, Adrienne M, Ito, Yoshinaga, Badrinath, Soumya, Tsoucas, Daphne, Franz, Bettina, May, Jr, Kenneth F, Harvey, Christopher J, Kobold, Sebastian, Pyrdol, Jason W, Yoon, Charles, Yuan, Guo-Cheng, Hodi, F Stephen, Dranoff, Glenn, Wucherpfennig, Kai W

“…MICA and MICB are expressed by many human cancers as a result of cellular stress, and can tag cells for elimination by cytotoxic lymphocytes through natural…”
Get full text

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials by Schadendorf, Dirk, Wolchok, Jedd D, Hodi, F Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C Lance, Lao, Christopher D, Chesney, Jason, Robert, Caroline, Grossmann, Kenneth, McDermott, David, Walker, Dana, Bhore, Rafia, Larkin, James, Postow, Michael A

“…Purpose Approximately 40% of patients with advanced melanoma who received nivolumab combined with ipilimumab in clinical trials discontinued treatment because…”
Get full text

Ipilimumab for Patients with Relapse after Allogeneic Transplantation by Davids, Matthew S, Kim, Haesook T, Bachireddy, Pavan, Costello, Caitlin, Liguori, Rebecca, Savell, Alexandra, Lukez, Alexander P, Avigan, David, Chen, Yi-Bin, McSweeney, Peter, LeBoeuf, Nicole R, Rooney, Michael S, Bowden, Michaela, Zhou, Chensheng W, Granter, Scott R, Hornick, Jason L, Rodig, Scott J, Hirakawa, Masahiro, Severgnini, Mariano, Hodi, F. Stephen, Wu, Catherine J, Ho, Vincent T, Cutler, Corey, Koreth, John, Alyea, Edwin P, Antin, Joseph H, Armand, Philippe, Streicher, Howard, Ball, Edward D, Ritz, Jerome, Bashey, Asad, Soiffer, Robert J

“…Hematologic cancers that recur after allogeneic hematopoietic stem-cell transplantation are often difficult to treat. A small pilot study suggests that…”
Get full text

Ipilimumab and Its Toxicities: A Multidisciplinary Approach by Fecher, Leslie A., Agarwala, Sanjiv S., Hodi, F. Stephen, Weber, Jeffrey S.

“…The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice…”
Get full text

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors by Curigliano, Giuseppe, Gelderblom, Hans, Mach, Nicolas, Doi, Toshihiko, Tai, David, Forde, Patrick M, Sarantopoulos, John, Bedard, Philippe L, Lin, Chia-Chi, Hodi, F Stephen, Wilgenhof, Sofie, Santoro, Armando, Sabatos-Peyton, Catherine A, Longmire, Tyler A, Xyrafas, Alexandros, Sun, Haiying, Gutzwiller, Sabine, Manenti, Luigi, Naing, Aung

“…Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively…”
Get full text

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements by NISHINO, Mizuki, GIOBBIE-HURDER, Anita, GARGANO, Maria, SUDA, Margaret, RAMAIYA, Nikhil H, HODI, F. Stephen

“…Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements,…”
Get full text

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy by Luoma, Adrienne M., Suo, Shengbao, Williams, Hannah L., Sharova, Tatyana, Sullivan, Keri, Manos, Michael, Bowling, Peter, Hodi, F. Stephen, Rahma, Osama, Sullivan, Ryan J., Boland, Genevieve M., Nowak, Jonathan A., Dougan, Stephanie K., Dougan, Michael, Yuan, Guo-Cheng, Wucherpfennig, Kai W.

“…Checkpoint blockade with antibodies specific for the PD-1 and CTLA-4 inhibitory receptors can induce durable responses in a wide range of human cancers…”
Get full text